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Abstract
Background:	 The	 Clinical	 Understanding	 and	 Research	 Excellence	 in	ME/CFS	 group	
(CureME)	at	the	London	School	of	Hygiene	&	Tropical	Medicine	has	supported	and	un-
dertaken	studies	in	immunology,	genetics,	virology,	clinical	medicine,	epidemiology	and	
disability.	It	established	the	UK	ME/CFS	Biobank	(UKMEB),	which	stores	data	and	sam-
ples	from	three	groups:	participants	with	ME/CFS,	Multiple	Sclerosis	(MS)	and	healthy	
controls.	Patient	and	public	involvement	have	played	a	central	role	from	its	inception.
Aim:	To	explore	the	views	of	participants	with	ME/CFS	and	MS	on	CureME	research	
findings,	dissemination	and	future	biomedical	research	priorities.
Method:	 Five	 ME/CFS	 and	 MS	 focus	 groups	 were	 conducted	 at	 two	 UK	 sites.	
Discussions	were	transcribed	and	analysed	thematically.
Results:	A	total	of	28	UKMEB	participants	took	part:	16	with	ME/CFS	and	12	with	MS.	
Five	themes	emerged:	(a)	Seeking	coherence:	participants’	reactions	to	initial	research	
findings;	(b)	Seeking	acceptance:	participants	explore	issues	of	stigma	and	validation;	(c)	
Seeking	a	diagnosis:	participants	explore	issues	around	diagnosis	in	their	lives;	(d)	Seeking	
a	better	future:	participants’	ideas	on	future	research;	and	(e)	Seeking	to	share	under-
standing:	 participants’	 views	 on	 dissemination.	 Focus	 groups	 perceived	 progress	 in	
ME/CFS	and	MS	research	in	terms	of	“putting	together	a	jigsaw”	of	evidence	through	
perseverance	and	collaboration.
Conclusion:	This	study	provides	insight	into	the	emotional,	social	and	practical	 impor-
tance	of	research	to	people	with	MS	and	ME/CFS,	suggesting	a	range	of	research	topics	
for	the	future.	Findings	should	inform	biomedical	research	directions	in	ME/CFS	and	MS,	
adding	patients’	voices	to	a	call	for	a	more	collaborative	research	culture.
2  |     LACERDA Et AL.
1  | INTRODUC TION
The	 Myalgic	 Encephalomyelitis/Chronic	 Fatigue	 Syndrome	 (ME/
CFS)	research	group	at	the	London	School	of	Hygiene	and	Tropical	
Medicine	has	been	a	pioneer	in	the	field	of	participant-	led	research,	
with	patients,	 carers	and	charity	 stakeholders	working	alongside	
medical	researchers	in	the	planning	and	development	of	research	
projects.1,2	 The	 group	 has	 developed	 the	 UK	ME/CFS	 Biobank2 
(UKMEB),	 a	 biomedical	 research	 resource	 to	 maximize	 research	
efforts,	 using	 a	 similar	 participatory	 approach.1	 Blood	 samples	
collected	from	people	with	ME/CFS	(PWME)	are	stored	alongside	
those	 from	participants	with	Multiple	Sclerosis	 and	healthy	 con-
trols,	 with	 detailed	 clinical	 and	 socio-	demographic	 data	 on	 each	
participant.
Our	 research	 team	 (CureME)	 uses	 the	 data	 and	 samples	 from	
the	UKMEB	 for	 studies	 in	 immunology,	 genetics,	 virology,	 clinical	
medicine,	epidemiology	and	disability	 in	ME/CFS.	We	also	 receive	
applications	from	national	and	international	research	teams	wishing	
to	use	biosamples	and/or	data	for	studies.	Decisions	on	whether	to	
release	samples	consider	not	only	the	quality	of	scientific	design,	but	
also	the	potential	benefit	for	PWME.3	Within	this	context,	we	con-
sider	the	understanding	of	the	meaning	and	importance	of	research	
findings	 to	 PWME	 of	 paramount	 importance,	 and	 their	 resultant	
views	on	biomedical	research	priorities.
ME/CFS	is	a	disease	characterized	by	unexplained	incapacitating	
fatigue	for	over	6	months	accompanied	by	other	variable	symptoms,	
leading	to	substantial	reductions	in	functional	ability;4,5	population	
prevalence	rates	are	estimated	at	around	0.2%	to	0.4%.6	At	its	most	
severe,	 it	 can	 result	 in	 patients	 becoming	 housebound,	 unable	 to	
mobilize	without	support,	or	sometimes	bedridden.7	ME/CFS	often	
affects	young	people	and	has	considerable	social	and	economic	im-
pacts,	due	to	its	chronic	nature.8,9	The	question	of	interventions	for	
ME/CFS	remains	complex	and	controversial,	with	differing	interpre-
tations	 of	 existing	 research	 evidence	 and	 no	 universally	 accepted	
treatment	approach.10
Biomedical	 studies	 in	 immunology,11-13	 virology8,14 and neurol-
ogy15-17	 and	 other	 specialty	 fields18-20	 have	 attempted	 to	 explain	
disease	pathways	 in	ME/CFS,	but	 research	findings	are	not	always	
reproducible.21	 The	 aetiology	 remains	 elusive,	 and	 in	 the	 absence	
of	 any	 confirmatory	diagnostic	 tests,	 diagnosis	 is	 based	on	 clinical	
history	when	other	possible	causes	of	fatigue	have	been	excluded.	
The	lack	of	a	diagnostic	test	or	biomarker	means	that	many	patients	
experience	scepticism	from	health	professionals,	employers	and	oth-
ers;	this	sense	of	stigma	is	a	substantial	emotional	burden	for	many	
patients.22
Multiple	 sclerosis	 (MS)	 was	 chosen	 as	 a	 comparison	 dis-
ease	 for	 ME/CFS,	 because	 while	 MS	 patients	 also	 experience	
chronic	 fatigue	 and	 disabling	 symptoms,	 the	 aetiology	 of	MS	 is	
comparatively	 well	 understood	with	 definitive	 diagnostic	 tests.	
People	with	MS	 have	 a	 broadly	 similar	 experience	 of	 disability,	
restricted	lifestyle	and	stress	contingent	to	the	illness,	but	with-
out	the	specific	challenges	presented	by	lack	of	a	diagnostic	test	
or	social	stigma.
For	this	study,	we	explored	the	ideas	of	the	UKMEB	participants	
with	MS	and	ME/CFS	on	our	preliminary	biomedical	research	find-
ings	and	their	dissemination,	and	on	future	biomedical	research	pri-
orities.	The	engagement	of	both	groups	of	 study	participants	was	
critical	to	fully	explore	the	different	perspectives	that	might	be	of-
fered	according	to	their	disease	narratives.
1.1 | Aim
To	contribute	to	empowering	the	voices	of	the	communities	involved	
by	exploring	the	reactions	of	research	participants	with	ME/CFS	and	
MS	to	preliminary	research	findings,	their	reflections	on	approaches	
to	dissemination	and	their	views	on	future	biomedical	research	pri-
orities,	 building	 on	our	 established	participatory	 approach	 in	ME/
CFS	research.
2  | METHODS
We	conducted	five	focus	group	interviews	in	July	2017.	Three	groups	
were	held	in	London	and	two	in	Norwich.	The	groups	comprised	28	
research	participants,	n	=	16	with	ME/CFS	(nine	females	and	seven	
males)	and	n	=	12	with	MS	(seven	females	and	five	males).
A	moderator	 led	 each	 group	 supported	 by	 a	 second	 researcher;	
no	other	observers	were	present.	In	London,	the	ME/CFS	participants	
were	grouped	by	gender	with	the	men’s	group	led	by	a	male	moderator	
(LN)	and	the	women’s	group	led	by	a	female	moderator	(EL).	All	other	
groups	were	mixed	gender	and	led	by	female	researchers	(CK	and	EL).	
Participants	gave	written,	 informed	consent	prior	to	taking	part.	The	
London	and	Norwich	groups	were	held	on	different	days	with	partic-
ipants	attending	a	presentation	of	preliminary	research	findings	from	
CureME	prior	to	their	focus	group.	The	programme	for	the	day	is	shown	
in	Box	1.	The	questions	provided	were	previously	discussed	and	refined	
among	the	authors,	with	input	from	an	external	qualitative	researcher.
The	research	team,	together	with	their	qualifications	and	experi-
ence	are	listed	at	the	end	of	the	paper.
2.1 | Patient and public involvement in study design
The	 CureME	 Steering	 Committee,	 which	 includes	 expert	 stake-
holder	advisors,	ME/CFS	charity	representatives,	PWME	and	carers,	
provided	feedback	on	the	design	of	the	study	and	the	program	for	
the	focus	group	days.
K E Y W O R D S
chronic	fatigue	syndrome,	focus	groups,	multiple	sclerosis,	myalgic	encephalomyelitis,	patient	
and	public	involvement,	qualitative	research
     |  3LACERDA Et AL.
2.2 | Participant selection
Participants	were	drawn	from	the	380	people	who	had	contributed	
data	and	blood	 samples	 to	 the	UKMEB.	 Initially,	100	potential	 re-
cruits	were	randomly	selected	to	include	a	range	of	illness	severity,	
illness	duration,	age	and	gender	with	selection	thereafter	purposive.	
The	research	nurse	approached	participants	by	telephone	and/or	e-
mail;	13	individuals	who	were	too	unwell	to	participate,	declined	or	
subsequently	dropped	out.
2.3 | Venues
The	 presentations	 and	 focus	 groups	 in	 London	 were	 held	 at	 the	
London	 School	 of	 Hygiene	 and	 Tropical	 Medicine,	 and	 those	 in	
Norwich	 at	 a	 conference/event	 centre.	 Participants	 travelling	 to	
London	were	offered	reimbursement	for	overnight	accommodation	
in	 recognition	 that	 some	would	be	 too	unwell	 to	 return	home	 the	
same	day.	Both	venues	were	wheelchair	 friendly,	and	quiet	 rooms	
with	sofas	were	provided	for	rest	breaks.
2.4 | Content of research presentation
Prior	to	each	focus	group,	participants	viewed	a	30-	min	presenta-
tion	 (by	LN,	EL	and	CK	in	Norwich;	and	by	LN	and	JC	 in	London),	
which	 included	 the	 rationale	 for	 carrying	out	 the	 studies,	 the	 re-
cruitment	 process,	 and	 the	 preliminary	 study	 findings.	 All	 analy-
ses	compared	the	UKMEB	data	and	samples	from	PWME,	people	
with	 MS	 and	 healthy	 participants.	 ME/CFS	 participants	 were	
subgrouped	as	mild/moderately	and	severely	affected.	The	socio-	
demographic	and	symptom	progression	findings	resulted	from	anal-
yses	of	a	bespoke	questionnaire	previously	piloted	by	the	research	
group,3	 while	 disability	 and	 quality	 of	 life	 were	 measured	 using	
the	SF-	36v2TM	Health	Survey.23	The	laboratory-	based	findings	in-
cluded:	reports	on	immune	responses	(particularly	on	the	number	
and	functioning	of	natural	killer	(NK)	cells),	the	presence	or	absence	
of	antibodies	against	herpes	viruses,	and	the	gene	expression	pro-
filing	of	the	groups.
2.5 | Data collection
Focus	 groups	 were	 audio-	recorded	 and	 transcribed	 verbatim.	 All	
transcriptions	were	anonymized	using	numbered	codes	for	each	par-
ticipant,	replacing	personal	identifiable	data	with	bracketed	generic	
titles.	Field	notes	were	taken	during	the	focus	groups.
2.6 | Data analysis
The	data	analysis	was	conducted	by	two	qualitative	researchers	(EL	
and	CM),	using	thematic	analysis	to	 identify	“patterns	of	meaning”	
across	the	transcripts	of	the	focus	group	discussions.	This	inductive	
approach	 followed	 the	 procedures	 for	 Thematic	 Analysis	 recom-
mended	by	Braun	and	Clarke.24
After	 listening	 to	 the	 audio-	recordings	 and	 reading	 the	 tran-
scripts	to	become	familiar	with	the	materials,	the	researchers	(EL	and	
CM)	carried	out	a	preliminary	analysis	on	paper	to	draft	initial	codes	
and	note	issues	of	interest.	The	transcripts	were	then	uploaded	onto	
NVivo	11.25	This	software	programme	facilitated	data	management	
and	enabled	an	audit	trail	in	which	decisionmaking	processes	could	
be	tracked	throughout	the	analysis	 in	a	 transparent	manner.	Audit	
trails	provide	a	recognized	strategy	for	increasing	the	credibility	and	
reliability	of	qualitative	research.26
After	 data	 coding	 and	 coding-	scheme	 generation,	 codes	 were	
organized	into	potential	themes	to	describe	the	analysed	data.	In	an	
iterative	process,	 these	 themes	were	checked	 for	consistency,	 co-
herence,	and	meaningfulness.	To	enhance	dependability,	EL	and	CM	
independently	analysed	all	transcripts,	holding	data	review	sessions	
to	discuss	clustering	of	codes	into	themes	and	emergent	theme	ti-
tles.	 Negative	 case	 analyses	 (seeking	 out	 disconfirming	 examples)	
BOX 1 Program for focus group day
1)	Greeting	and	explanation	of	the	program	for	day
2)	Presentation	of	research	findings	in	lay	terms	with	time	for	
questions	for	clarification
3)	Informed	consent	process	–	explanation	(with	time	for	ques-
tions)	and	signatures
1)	Lunch	interval	with	lunch	provided
2)	Focus	groups	discussions
3)	Interval
4)	Focus	group	discussions
5)	Conclusions
Group	tasks	and	prompts
Focus	group	–	task	1
1)	Tell	me	what	you	think	about	the	research	findings	that	were	
presented?
2)	Do	the	research	findings	seem	to	make	sense	when	you	think	
of	your	personal	experience	of	ME/CFS	or	MS?
3)	Are	there	any	additional	questions	 that	you	think	could	be	
answered	by	this	research?
4)	Do	you	believe	the	way	diagnosis	is	made	may	have	impacted	
on	 the	 study	 results,	 how	do	 you	 think	 diagnosis	 of	ME/CFS	
should	be	made?	(For	the	groups	with	ME/CFS	only).
Focus	group	–	task	2
During	 the	 second	 part	 of	 the	 discussion,	 participants	 were	
asked	to	discuss	in	pairs	the	following	questions.
5)	How	would	you	explain	the	findings	to	another	person	who	
hasn’t	experienced	the	disease?
6)	How	do	you	think	these	results	should	be	make	public	for	the	
research	community,	the	health	professionals	and	the	public	in	
general?
After	10	min,	each	pair	were	asked	to	present	their	ideas.	The	
full	group	was	then	asked	to	discuss	the	key	messages	that	need	
to	be	conveyed	and	on	the	best	means	to	communicate	them.
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safeguarded	against	 reaching	a	 final	 thematic	scheme	prematurely	
and	ensured	we	represented	all	views.27
3  | RESULTS
We	conducted	five	focus	groups	in	which	28	participants	took	part	
(17	ME/CFS,	 11	MS).	 Table	1	 summarizes	 the	 composition	 of	 the	
focus	groups,	and	Table	2	summarizes	participant	characteristics.
We	 present	 here	 the	 five	 key	 themes	 emerging	 from	 the	 the-
matic	analysis,	supported	by	verbatim	quotes	(Table	3).	For	ease	of	
reference,	quotes	are	numbered	within	the	text	using	the	label	(Q1),	
(Q2),	etc.
3.1 | Theme 1: Seeking coherence: Participants’ 
reactions to initial research findings
All	 participants	 express	 a	 compelling	 need	 to	make	 sense	of	 their	
illness	 experience.	Research	was	 seen	 as	 a	means	 to	 achieve	 this,	
offering	hope	of	putting	together	a	“jigsaw”	of	evidence	which	might	
provide	answers	(Q1).	Participants	seemed	to	be	critically	examining	
the	research	findings	 in	the	 light	of	their	own	knowledge	and	per-
sonal	experience,	taking	on	an	“investigator”	role,	rather	than	being	
passive	recipients	of	research	information.
Participants	 suggested	 that	 ME/CFS	 and	 MS	 are	 complex	 ill-
nesses	and	that	finding	answers	was	also	likely	to	be	complex	(Q2).	
They	emphasized	a	need	 for	 interconnected	 thinking	 in	which	dif-
ferent	physiological	 factors	might	contribute	 to	 the	 illness,	 includ-
ing	immune	function	(Q3),	pathogens,	particularly	viruses	(Q4,	Q5),	
physical	or	emotional	trauma	and	genetics	(Q6).	The	role	of	environ-
mental	factors,	food	and	chemicals	in	triggering	CFS/ME	onset	and/
or	worsening	symptoms	was	of	particular	interest	(Q7).
A	major	concern	voiced	by	PWME,	was	the	need	to	differentiate	
between	people	whose	ME/CFS	is	defined	according	to	specific	di-
agnostic	criteria,	and	those	with	other	forms	of	chronic	fatigue	(Q8),	
as	without	such	clarification,	research	results	could	be	distorted	or	
diluted.	ME/CFS	participants	requested	that	it	would	be	made	clear	
in	publications	that	people	with	chronic	fatigue	who	do	not	fulfil	the	
criteria	for	ME/CFS	are	differentiated	in	UKMEB	studies.
Participants	also	noted	that	subgroups	within	ME/CFS	had	differ-
ences	in	onset	patterns	(eg,	viral	onset	or	non-	viral),	predominating	
symptoms	(Q9)	and	levels	of	severity	(ie,	mild/moderate	or	severe).	
Participants	 showed	particular	 interest	 in	gene	expression	 results,	
in	which	those	with	severe	ME/CFS	appeared	to	be	more	similar	to	
those	with	MS	than	those	with	mild/moderate	ME/CFS	(Q10).	There	
was	ensuing	debate	on	whether	severe	ME/CFS	might	have	funda-
mental	differences	to	mild/moderate	ME/CFS,	or	whether	severity	
in	ME/CFS	should	be	regarded	as	simply	a	continuous	spectrum.
Differentiating	different	subgroups	within	MS	also	emerged	as	
a	core	interest,	with	participants	citing	the	categories	of	“relapsing-	
remitting	MS,”	“primary-	progressive	MS”	and	“secondary-	progressive	
MS”	(Q11).	Overall,	MS	participants	felt	they	had	reasonable	clarity	
about	 illness	mechanisms,	 but	wanted	 to	 know	why	MS	might	 be	
triggered,	 discussing	 factors	 such	 as	 genetic	 susceptibility,	 viruses	
and	other	pathogens	and	physical	or	emotional	trauma	(Q12).
Within	an	overarching	need	to	find	coherence	by	making	sense	
of	often	confusing	symptoms,	one	of	the	most	vividly	expressed	is-
sues	was	the	need	for	a	proven	diagnostic	test	for	ME/CFS,	which	is	
the	focus	for	the	next	theme.
3.2 | Theme 2: Seeking a diagnosis: Participants 
explore issues around diagnosis in their lives
Participants	with	ME/CFS	described	a	 situation	 in	which	 lack	of	 a	
diagnostic	test	and	uncertain	aetiology	left	 individuals	feeling	lost,	
desperate	to	make	sense	of	their	symptoms,	and	often	unsupported	
by	health	professionals	(Q13,	Q14).	Research	was	depicted	not	only	
as	offering	hope	of	understanding	their	symptoms,	but	also	of	being	
able	to	demonstrate	proof	of	disease	to	regain	self-	respect	and	re-
spect	from	others.
In	 contrast,	 as	MS	participants	noted,	MS	 is	 an	 illness	with	 a	
known	disease	process.	Nevertheless,	during	the	first	years	of	their	
illness,	three	of	the	MS	participants	had	been	mistakenly	diagnosed	
with	ME/CFS	(Q15),	and	two	had	their	symptoms	attributed	to	psy-
chological	 causes.	 Their	 accounts	 of	 these	 experiences	mirrored	
those	 of	 the	ME/CFS	 participants,	 describing	 a	 sense	 of	 “limbo”	
(Q16),	 with	 loss	 of	 self-	confidence	 and	 feelings	 of	 despair.	 The	
turning	 point	 in	 their	 illness	 trajectory	 appeared	 to	 be	 receiving	
a	definite	diagnosis	of	MS.	One	MS	participant	vividly	described	
his	 sense	of	 relief	at	 feeling	 that	he	was	 “not	going	mad,”	and	 to	
have	a	label	for	his	illness	(Q17).	Others	described	similar	feelings	
of	 restored	coherence,	being	able	 to	deal	with	 the	situation,	and	
being	able	to	communicate	their	 illness	to	others	without	fearing	
judgmental	reactions	(Q18,	Q19).	MS	participants	linked	receiving	
Location Members Group size Moderator Duration
Group	1 London Men	with	ME n	=	6 LN	(male) 1 h 23 min
Group	2 London Women	with	ME n	=	5 EL	(female) 1 h 12 min
Group	3 London Women	and	men	
with	MS
n	=	6 CK	(female) 1 h
Group	4 Norwich Women	and	men	
with	ME
n	=	5 EL	(female) 1 h 10 min
Group	5 Norwich Women	and	men	
with	MS
n	=	6 CK	(female) 1	h	9	min
TA B L E  1  Summary	of	focus	groups
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a	diagnosis	not	only	with	a	sense	of	validation	and	restored	social	
acceptance,	but	also	 the	ability	 to	access	support	 (Q20).	 It	 is	 im-
portant	to	emphasize,	however,	that	for	some,	diagnosis	of	MS	had	
felt	completely	devastating,	with	no	positive	aspects,	described	by	
one	as	“the	biggest	kick	in	the	teeth	ever”	(Q21).
While	some	participants	with	MS	had	experienced	diagnosis	as	
pivotal	 to	 regaining	 coherence,	 validation	 and	 self-	respect,	 partici-
pants	with	ME/CFS	were	still	hoping	for	a	similar	turning	point.	When	
exploring	the	meaning	of	research	for	their	lives,	the	relationship	be-
tween	physical	proof	of	 illness	and	social	acceptance	emerged	as	a	
central	concept,	and	this	will	be	explored	further	in	the	next	theme.
3.3 | Theme 3. Seeking acceptance: Participants 
explore issues of stigma and validation
For	many	 of	 the	 participants	 with	ME/CFS,	 a	 central	 figure	 from	
whom	they	sought	acceptance	and	support	was	their	primary	care	
doctor	(GP).	In	the	absence	of	biomedical	tests	to	prove	illness,	many	
of	the	participants	felt	that	they	had	struggled	to	convince	their	GP	
that	they	were	physically	ill	and	relationships	had	become	strained.	
Some	 participants	 described	 experiences	 of	 feeling	 disbelieved,	 
un	supported	 or	 not	 “held”	 within	 medical	 relationships,	 although	
others	reported	that	they	had	a	good	relationship	with	their	current	
GP	who	gave	them	valued	support	(Q22).
Illuminating	reflections	were	offered	by	one	participant	who	had	
been	a	GP	prior	to	having	ME/CFS.	Recalling	personal	experiences,	
he	described	some	of	the	difficulties	experienced	by	GPs	when	pre-
sented	with	 a	 patient	 with	medically	 unexplained	 symptoms.	 The	
participant	noted	how	much	he	had	learned	as	a	doctor	since	experi-
encing	ME/CFS	himself	(Q25).
Feeling	judged	as	not	genuinely	ill	by	employers,	benefits	agen-
cies	and	friends	or	family	were	also	highlighted	by	ME/CFS	partici-
pants	as	well	as	by	MS	participants,	who	recalled	similar	experiences	
prior	to	diagnosis	(Q26).	ME/CFS	and	MS	participants	were	intrigued	
by	results	from	the	SF36v2™	questionnaire	viewed	earlier	in	the	day,	
suggesting	that	 the	 impact	of	 illness	on	social	 function	was	worse	
for	participants	with	ME/CFS	than	MS	(Q27).	Both	ME/CFS	and	MS	
participants	hypothesized	that	this	might	be	due	to	PWME	finding	it	
harder	to	feel	acceptance	from	others	and/or	self-	acceptance	with-
out	biomedical	proof	of	illness	(Q28).	Yet,	it	is	important	to	note	that	
participants	diagnosed	with	MS	also	described	situations	 in	which	
their	 illness	 impacted	 their	 social	 confidence.	 Unpredictable	 epi-
sodes	of	 incontinence	or	problems	with	being	misjudged	as	drunk	
due	 to	 poor-	balance	 could	 lead	 to	 considerable	 social	 embarrass-
ment	and	distress	(Q29).
Overall,	 the	 impact	 of	 illness	 on	 social	 acceptance	 and	 confi-
dence	emerged	as	a	major	concern,	which,	in	addition	to	the	illness	
symptoms,	adversely	affected	quality	of	 life.	Research	was	widely	
perceived	as	offering	hope	for	improved	quality	of	life,	and	the	next	
theme	explores	participants’	views	on	this.
3.4 | Theme 4. Seeking a better future: Participants’ 
ideas on future research
Participants’	suggestions	on	research	topics	tended,	perhaps	unsur-
prisingly,	to	be	illness-	specific.
TA B L E  2  Participant	characteristics
Characteristic
ME/CFS 
participants MS participants
Gender
Male 7 5
Female 9 7
Ethnicity
White	(British) 14 8
Indian 1 0
Black	British/Jamaican 1
White	(nationality	other	than	
British)
2
Other	ethnicity 1 1
Age	group
≥18	and	≤29 2
≥30	and	≤39 2
≥40	and	≤49 4 6
≥50	and	<60 8 6
Illness	duration
<2	years 4 1
≥2	years	and	≤5	years 4 1
>5	years	and	≤10	years 3 3
>10	years	and	≤20	years 4 3
>20	years 1 4
Illness	severity
Mild-	moderate 13 - 
Severe 3 - 
Diagnosis
ME/CFS	according	to	CDC	
1994a	and	Canadian	criteriab
12
ME/CFS	according	to	CDC	
1994	criteria	onlya
3
ME/CFS	according	to	
Canadian	criteria	onlyb
1
MS	according	to	NICE	
guidelinesc
12
Diagnostic	criteria
aFukuda	 K,	 Straus	 S,	 Hickie	 I,	 Sharpe	M,	Dobbins	 J,	 Komaroff	 A.	 The	
chronic	 fatigue	 syndrome:	 a	 comprehensive	 approach	 to	 its	 definition	
and	 study.	 International	 Chronic	 Fatigue	 Syndrome	 Study	Group.	 Ann	
Intern	Med.	1994;	953-	9.	
bCarruthers	B,	 Jain	A,	De	Meirleir	K,	 et	al.	Myalgic	encephalomyelitis/
chronic	 fatigue	 syndrome:	 clinical	 working	 case	 definition,	 diagnostic	
and	 treatment	 protocols.	 Journal	 of	 Chronic	 Fatigue	 Syndrome	
2003;	115.	
cNational	Institute	for	Clinical	Excellence.	Clinical	Guideline	8:	Multiple	
sclerosis	-	Management	of	multiple	sclerosis	 in	primary	and	secondary	
care.	In:	Conditions	NCCfC,	editor.	London:	National	Institute	for	Clinical	
Excellence; 2003. 
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The	ME/CFS	 participants	 saw	 finding	 a	 physical	 cause	 for	 the	
illness	as	the	main	priority.	They	considered	that	researchers	needed	
to	be	open	to	a	wide	range	of	possible	disease	causes	including	the	
investigation	of	immune	function,	mitochondrial	function	and	poten-
tial	 triggers	 for	ME/CFS	such	as	vaccinations	 (Q30),	viruses	 (Q31),	
diet,	and	chemicals	or	environmental	toxins	(Q32).	They	expressed	
particular	appreciation	of	the	use	of	gene	expression	profiling	as	a	
means	 of	 investigating	 potential	 dysfunction	 across	 physiological	
systems	(Q33).
Participants	 also	 suggested	 comparing	 blood	 samples	 from	
PWME	 diagnosed	 according	 to	 specific	 diagnostic	 criteria	 (eg,	
Canadian	Consensus	Criteria)	to	those	with	other	forms	of	chronic	
fatigue,	in	the	hope	that	this	might	offer	clues	about	underlying	ill-
ness	mechanisms	(Q7).	Other	comparisons	suggested	were	of	onset	
patterns	or	predominating	symptoms.	Participants	noted	that	recov-
ery	rates	for	ME/CFS	were	better	in	children	than	adults,	and	sug-
gested	research	to	investigate	this	phenomenon.
In	contrast,	participants	with	MS	expressed	 feeling	 reasonable	
clarity	 about	 the	 cause	 of	 their	 illness,	 although	 the	 search	 for	 a	
cure	felt	elusive	(Q33).	Emotions	elicited	by	taking	part	in	research	
appeared	 complex,	 including	 pleasure	 or	 pride	 at	 feeling	 able	 to	
contribute	to	work	which	could	help	future	generations,	alongside	
sadness	that	a	cure	felt	unlikely	in	participants’	own	lifetime	(Q34,	
Q35).	Participants	were	also	curious	to	know	why	they	had	devel-
oped	MS	personally,	highlighting	issues	such	as	heredity,	and	trigger-
ing	events	such	as	surgery,	injury	or	other	trauma.
Both	 ME/CFS	 and	 MS	 participants	 were	 intrigued	 by	 results	
which	had	found	impact	of	 illness	on	pain,	fatigue	and	social	func-
tion	to	be	worse	in	ME/CFS	than	MS.	Several	ME/CFS	participants	
wanted	to	see	such	comparisons	extended,	for	example,	to	compare	
electronically	measured	activity	and	sleep	(Q37	Q38).
Dissemination	of	research	results	was	perceived	as	a	crucial	route	
to	influencing	attitudes,	and	this	is	the	subject	of	our	final	theme.
3.5 | Theme 5: Seeking to promote understanding; 
participants views on dissemination
We	asked	participants	to	share	their	 ideas	about	how	research	re-
sults	might	best	be	disseminated,	considering	target	audiences,	sug-
gested	strategies,	hopes	and	concerns.
Recommended	 target	 audiences,	 predictably,	 included	 doctors	
(especially	 GPs),	 PWME	 or	MS	 and	 their	 families	 or	 carers,	 social	
workers,	benefits	agency	professionals	and	 the	general	public,	es-
pecially	young	people.
Tailoring	the	style	of	dissemination	to	the	audience	was	consid-
ered	 particularly	 important	 (Q39),	 with	 easy-	to-	read	 scientific	 ex-
planations	 illustrated	with	personal	stories	for	a	general	readership	
thought	 likely	 to	 gain	 the	 most	 media	 attention,	 especially	 if	 the	
stories	were	emotionally	compelling	or	linked	to	celebrities	(Q40).	In	
contrast,	 for	medical	and	scientific	audiences,	peer-	reviewed	publi-
cation	in	reputable	journals	was	considered	essential	(Q41),	with	the	
addition	of	brief	summaries	(“one	pagers”)	to	reach	busy	GPs	or	other	
professionals	who	might	not	have	time	to	read	longer	articles	(Q42).
Strategies	 for	 publicizing	 results	 included	 mainstream	 media,	
such	as	newspapers,	radio	and	TV.	Patient	organisations	were	also	
thought	 a	 valuable	 conduit	 for	 communicating	 research	 results.	
While	social	media	was	discussed	as	a	means	of	communication,	this	
raised	more	concerns	than	enthusiasm,	due	to	the	challenge	of	con-
densing	complex	topics	into	relatively	few	words.
For	 participants	 with	MS,	 an	 overarching	 priority	 for	 dissemi-
nation	appeared	to	be	updating	doctors,	people	with	MS,	and	their	
families	and	friends	on	research	progress	without	raising	unrealistic	
hopes	 of	 cure,	which	 some	 found	distressing	 or	 frustrating	 in	 the	
past	(Q43).	A	priority	was	to	ensure	that	any	dissemination	was	con-
cise,	positive	and	realistic	(Q44).
Participants	suggested	that	dissemination	of	early	results,	even	
unspectacular	ones,	could	provide	hope,	 tempered	by	 the	realistic	
acknowledgement	that	small	knowledge	increments	could	gradually	
lead	towards	greater	understanding	(Q47).	Participants	emphasized	
the	 importance	 of	 collaboration	 rather	 than	 competition	 between	
research	teams	(Q48).
The	concept	of	research	collaboration	recurred	throughout	the	
discussions,	underpinning	participants’	hopes	for	the	future.	Within	
this	context,	they	appreciated	being	treated	as	respected	partners	
by	the	research	team,	listening	to	their	views	and	keeping	them	in-
formed	(Q49).	Participants	reflected	on	their	own	place	within	the	
quest	for	a	better	future	through	scientific	understanding,	as	people	
who	had	“bought	into”	the	research	process	(Q50,	Q51)	through	con-
tributing	not	only	blood	samples,	but	their	time	and	effort,	ideas,	ex-
periences	and	hopes;	expressing	enthusiasm	by	the	possibility	that	
they	too	could	genuinely	“make	a	difference”	to	the	research	journey	
ahead	(Q52,	Q53).
4  | DISCUSSION
4.1 | Summary of key results
In	recent	years,	patient	perspectives	have	become	increasingly	im-
portant	 in	 informing	the	 is	planning,	conduct	and	dissemination	of	
research.28	 In	 this	 study,	 participants	 with	ME/CFS	 and	MS	 illus-
trated	 the	 importance	of	 research	as	means	of	 seeking	coherence	
to	make	sense	of	their	 illness	 (Theme	1),	seeking	diagnostic	clarity	
(Theme	 2)	 and	 proof	 of	 illness	 by	 which	 they	 could	 gain	 accept-
ance	and	from	the	medical	profession	and	from	society	(Theme	3).	
Participants	 offered	 ideas	 on	 future	 research	 priorities	 (Theme	 4)	
and	recommendations	for	dissemination	(Theme	5).
A	key	aim	in	this	study	was	to	elicit	patient	views	on	biomedical	
research	priorities	for	the	future.	Overall,	 the	research	topics	pro-
posed	fitted	already	familiar	categories,	such	as	immunological	and	
mitochondrial	dysfunction	 in	ME,	 triggers	 including	viruses,	 toxins	
and	 other	 pathogens,	 and	 biomedical	 differences	 between	 differ-
ent	subgroups.	For	participants	with	MS,	the	search	for	a	cure	was	
viewed	as	paramount,	though	participants	were	also	interested	in	in-
vestigating	genetic,	viral,	and	immunological	factors	in	triggering	the	
illness.	While	not	unexpected,	these	findings	have	value	in	confirm-
ing	findings	from	our	previous	patient	consultation	work.2	What	this	
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TA B L E  3  Exemplifying	quotes	arranged	by	theme
Exemplifying quotes
Theme	1:	Seeking	coherence Q1.	It’s	a	big	jigsaw	that	you	need.	(P3,	male,	ME,	FG1)
Q2.	I	think	the	reason	we	don’t	know	what	causes	CFS	is	because	it’s	really,	really	complicated	(P16,	female,	ME,	
FG3)
Q3	My	understanding	was	that	there	seems	to	be	a	difference	in	the	way	the	immune	system	reacts	to	the	
introduction	of	a	pathogen,	and	this	is	something	to	do	with	the	answer	we	need	to	find	in	the	future,	what’s	
happening	to	the	immune	system.	(P1,	male,	ME,	FG1)
Q4.	I’ve	always	wondered	whether	some	viral	infection	or	something	like	that	was	what	triggered	the	MS.	(P7,	
female,	MS,	FG2)
Q5.	I’m	particularly	interested	in	the	genetic	expression	of	whether	the	immune	system	is	reacting	properly	to	
pathogens	or	not.	(P4,	male	with	ME,	FG1)
Q6.	If	they	say	there’s	a	hereditary	link	through	it,	I’ve	got	nothing	in	my	family.	I’m	the	first,	so	what’s	gone	on	
with	my	genes	to	kick	this	all	off?	(P24,	male,	MS,	FG5)
Q7.	During	that	time,	in	a	few	weeks	leading	up	to	me	with	months	being	diagnosed	with	ME,	there	were	several	
chemicals	used	in	the	house	usually	by	myself,	paint	strippers	to	take	off	all	wallpapers,	moulds,	paints….I	just	
wondered	whether	there	was	any	connection	with	chemicals,	moulds,	on	the	immune	system	or	that	sort	of	
thing?	(P19,	male,	ME,	group	4)
Q8.	The	fact	that	Biobank	breaks	down	Canadian	criteria	and	non-	Canadian	criteria	was	important.	(P3,	male	
with	ME,	FG1)
Q9.	There	needs	to	be	a	lot	more	grouping.	ME	is	just	too	wide	a	term…His	is	more	brain-	based,	mine	is	more,	for	
me	it	feels	more	muscle	and	that	sort	of	side.	(P5,	male	with	ME,	FG1)
Q10.	There	seems	to	be	a	fairly	big	distinction	between	mild,	moderate	and	severe,	and	from	that	last	graph	it	
almost	looked	as	if	they	were	two	separate	conditions	because	they	were	so	different	between	the	severe	
section	and	the	mild-	moderate	section.	(P6,	male,	ME,	FG1)
Q11.	We’ve	got	relapsing,	remitting,	primary	progressive,	secondary	progressive.	Is	there	anything	in	that?	I	have	
no	idea,	because	they	obviously	present	differently	and	they	are	treated	differently.	(P7,	male,	MS,	FG2)
Q12.	We	all	seem	to	have	had	some	sort	of	virus	and	we	all	seem	to	have	had	some	sort	of	trauma.	You	put	those	
together	with	the	extraction	of	the	genetic	information.	Whether	there’s	anything?	I	don’t	think	you	should	
ignore	the	virus	thing	and	I	don’t	think	you	should	ignore	the	trauma	side	because	if	you	find	something	out	in	
the	genetics,	are	there	triggers	that	then	tie	into	your	psychological	and	physical	findings?	(P25,	female,	MS,	
FG5)
Theme	2:	Seeking	a	diagnosis Q13.	It’s	just	the	hope	that	you’ll	know	what	it	is,	what	the	cause	is	and	that	there	can	be	a	test	for	it	because	I	
think	we	are	treated	so	differently	to	any	other	condition	where	you	can	say	there’s	a	cause,	there’s	a	test	for	it.	
(P18,	female,	ME,	group	4)
Q14.	I	think	that’s	what	we’re	all	desperate	to	see,	isn’t	it,	something	that	says	there’s	something	physically	
wrong	with	you’	(P17,	female,	ME,	group	3)
Q15.	I	got	diagnosed	originally	with	ME.	I	went	through	five	years	with	really	bad	times	with	it.	(P24,	male,	MS,	
group	5).
Q16.	Yes,	that	being	left	in	limbo,	you	don’t	know	where	you	are.	I	was	told	everything.	“You’re	just	depressed.	
Go	and	get	some	more	happy	pills”	and	all	the	rest	of	this	sort	of	stuff.	You	know	something	is	wrong,	but	you’re	
not	sure	what	it	is.	(P28,	male,	MS,	group	5))
Q17.	It	was	such	a	relief	to	have	that	labelled	and	to	know	that	I	wasn’t	going	mad	in	the	intervening	ten	or	
eleven	years	or	whatever.	(P28,	male,	MS,	group	5)
Q18.	I	think	that	was	the	thing	with	ME.	I	couldn’t	go	out	and	mingle	because	everyone	will	just	label	you	a	
malingerer,	“There’s	nothing	wrong.	He’s	got	ME.	What’s	that?	There’s	nothing	wrong	with	him.”	When	you’ve	
got	MS	everyone	goes,	“Oh.”	I’ve	got	MS.”	“Oh,	fine,	yes.	Alright.”	(P24,	male	MS	Group	5)
Q19.	Eventually	the	diagnosis,	I	was	like,	“Oh,	thank	God	for	that.	Now	I	can	move	on.”	(P27,	male,	MS,	group	5)
Q20.	Without	a	clear	diagnosis,	you	don’t	get	the	support	structure.	I	was	left	in	limbo,	having	had	one	incident,	
to	then	survive	until	I	got	another	incident	worthy	of	note.	Then	when	you’ve	got	that	they	said,	“Yes,	you’ve	
got	MS”	(P28,	male	MS,	group	5)
Q21.	I	think	for	me,	to	actually	be	diagnosed	was	the	biggest	kick	in	the	teeth	I	have	ever,	ever	had.	(P23	male,	
MS,	group	5)
Theme	3:	Seeking	acceptance Q22.	They	don’t	take	like	an	overview,	you	don’t	feel	held	by	them,	you	don’t	feel	safe.	Like	they’re	looking	at	
you,	I’ve	actually	got	a	GP	now	that	is	doing	that.	(P18,	female,	ME,	group	4)
(Continues)
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Exemplifying quotes
Q23.	I	almost	feel	like	on	my	record	there’s	so	much.	I	actually	found	a	lump	and	I	delayed	for	a	year	going	because	
I	was	just	like,	I	actually	said,	“I	can’t	have	another	thing,	like	I	can’t,	they’ll	ban	me.”	(P18,	female,	ME	group	4)
Q24.	What	my	neurologist	said	to	me,	“Count	everything	else	first,	see	what	else	it	might	be,	then	the	last	thing	
it’ll	be	is	MS.”	He	said,	“Don’t	put	it	top	of	the	list,”	he	said,	“because	you	start	putting	symptoms	and	ignoring	
them	and	thinking	it’s	MS	and	really	there’s	another	big	health	issue	going	on.”	(P24,	male,	MS	group	5)
Q25.	I	learnt	an	awful	lot	more	about	it	after	suffering	and	as	time	goes	on	you	think,	“Oh	yes,	that	symptom	is	
compatible,”	and	understand	a	lot	more.	(P19,	male,	ME,	group	4)
Q26.	I’m	mentally	far	stronger	now	than	I	was	when	I	was	in	that	two	to	three	year	period	where	work	were	
telling	me	there	was	nothing	wrong	with	me	and	I	was	only	pulling	a	sickie…	Eventually	the	diagnosis,	I	was	like,	
“Oh,	thank	God	for	that.	Now	I	can	move	on.”	(P27,	male,	MS,	group	5)
Q27.	That	was	the	thing	that	came	up	for	me	as	well	that	I	anticipated	that	people	with	MS	would	have	probably	
more	fatigue	and	more	restriction	socially,	but	it	seemed	to	be	the	ME	group	that	were	more	affected.	(P20,	
female,	ME,	group	4)
Q28.	When	they	had	the	right-	hand	chart—and	I	think	it	said	that	socially	and	mentally	we	became	a	bit	stronger,	
if	I	read	the	chart	correctly—in	seeing	that	I	thought,	“Well,	it’s	probably	because	we	do	have	a	definite	
diagnosis	of	a	definite	condition	that	you	can	definitely	get	your	head	round,	however	long	that	takes	and	
whatever	adaptations	you	have	to	make.	(P25,	female,	MS,	group	5)
Q29.	You	go	out	on	a	social	event,	like	a	bar	you’re	in	or	something	else,	and	I	still	really	think	harder,	“I	need	a	
wee,	but	I	don’t	want	to	get	up	because	they’ll	think	I’m	drunk.”	(P24,	male,	MS,	group	5)
Theme	4:	Seeking	a	better	
future
Q30.	My	main	thing	as	far	as	I’m	concerned,	I	think	vaccinations	are	often	overlooked.	Vaccinations	have	
transformed	the	health	of	the	world	basically,	but	I	do	think	vaccinations	are	a	trigger	for	some.	(P4,	male,	ME,	
group	1)
Q31.	Is	there	anything	being	done	to	say	certain	viruses	could	well	be	the	trigger?	(P6,	male,	ME,	group	1)
Q32.	During	that	time,	in	a	few	weeks	leading	up	to	me	with	months	being	diagnosed	with	ME,	there	were	
several	chemicals	used	in	the	house	usually	by	myself,	paint	strippers	to	take	off	all	wallpapers,	moulds,	paints.	
(P21,	female,	ME,	group	4)
Q33.	That	was	the	point	of	doing	the	gene	expression	work,	is,	rather	than	following	up	the	knowns,	and	the	
unknown	knowns,	etc.,	is	to	actually	try	to	look	globally	at	everything	we	can.	There	will	always	be	things	that	we	
don’t	even	think	of	to	look	at,	but	it	is	an	unbiased	approach	to	try	to	pull	things	out.	(P8,	female,	MS,	group	2)
Q34.	I’m	sat	here	thinking,	“What	did	I	expect	out	of	this?”	Maybe	somebody’s	going	to	say,	“Okay,	we’ve	found	a	
magical	cure,”	and	obviously	what	is	coming	back	to	me	is	telling	me	that	I’m	not	going	to	get	that	cure	within	
my	lifespan,	so	possibly	a	bit	sad.	(P9,	female,	MS,	group	2)
Q35.	I	think	most	of	us	realize	that	probably	we’re	a	little	bit	past	the	point	where	we’re	going	to	be	miraculously	
cured.	Well,	I	always	think	that	if	it	happens	it’s	great,	but	I’m	not	banking	on	it	happening	because	then	I’m	
going	to	be	disappointed	if	it	doesn’t.	(P25,	female,	MS,	group	5)
Q36.	I’m	glad	I’m	participating	in	this	and	that,	even	if	I	don’t	get	the	benefit,	the	future	generations	will	benefit	
from	it.(P11,	female,	MS,	group	2)
Q37.	It	was	quite	interesting,	not	positive,	I	wouldn’t	say,	but	interesting	to	see	that	the	pain	with	ME,	according	
to	your	research,	is	more	severe	than	MS.	I	found	that	really	bizarre	in	a	‘We	need	to	study	this	now,’	kind	of	
way.	(P13,	female,	ME,	group	3)
Q38.	An	objective	measure	of	that	would	be	to	use	technology	that	they	have	now	where	you	could	have	the	
actimeters,	like	they	were	showing	on	the	Doctor	in	the	House	where	they	had	a	watch	that	measured	their	
activity,	their	night,	their	sleep	and	that	sort	of	thing	would	then	back	up	actually	what	has	been	shown	by	
those	questionnaires.	Then	that	would	surely	be	a	very	good	measure	of	a	longitudinal	measure	of	each	
individual	and	then	compare	it	with	MS.	(P14,	female,	ME,	group	4)
Theme	5:	Seeking	to	share	
understanding
Q39.	If	it’s	going	out	in	any	form	to	the	general	public	it	wants	to	be	in	a	readable	format,	not	500	pages	of	
medical	comments	that	nobody	who’s	going	to	read	it	can	actually	understand.	(P6,	male,	ME,	group	1)
Q40.	But	you	do	need	to	thread	a	personal	story	through	it	somehow,	that’s	the	formula,	that’s	what	we’ve	
always	seen,	a	personal	story	that	illustrates	the	actual	research	but	it’s	the	kind	of	story	that	illustrates.	(P1,	
male,	ME,	group	1)
Q41.	I	think	it	would	be	good	if	you	could	get	the	results	in	a	fairly	mainstream	medical	journal.	Like,	I	don’t	
know,	the	BMJ.	You	get	a	synopsis	of	results	or	something	in	the	New	Scientist	publication	like	that,	that	
reaches	quite	a	wide	audience	as	well.	It	might	get	picked	up	by	newspapers	and	other	media.	(P19,	male,	ME,	
group	4)
TA B L E  3   (Continued)
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study	adds	to	our	understanding	is	a	vivid	contextualization	of	these	
specific	requests,	within	a	wider	and	more	personal	understanding	
of	how	biomedical	confirmation	of	an	illness,	or	lack	of	it,	can	impact	
the	patient’s	quality	of	life,	with	factors	including	social	acceptance,	
patient–doctor	relationships,	self-	confidence	and	support.
An	intriguing	finding	of	the	study	was	the	extent	to	which	some	
of	the	MS	participants	reported	feeling	disbelieved	by	doctors,	em-
ployers,	or	others	about	their	symptoms	prior	to	diagnosis.	Their	ac-
counts	of	distress	and	 loss	of	social	confidence	resulting	from	this	
resonate	with	the	experiences	of	ME/CFS	patients.	Within	this	con-
text,	 sharing	 research	 results	was	portrayed	not	only	as	providing	
information	to	medical	professionals,	families,	and	others	in	society,	
but	also	as	a	means	of	changing	attitudes.	Participants	called	for	a	
more	 collaborative	 research	 culture,	with	greater	 emphasis	on	ex-
plaining	where	new	knowledge	fitted	into	a	wider	“jigsaw”	of	knowl-
edge,	and	less	on	apparent	“breakthrough”	discoveries.	Participants	
expressed	 pleasure	 at	 having	 played	 a	 part	 in	 contributing	 to	 the	
current	research,	tempered	with	awareness	that	determination	was	
needed	for	the	research	journey	ahead.
4.2 | Strengths and weaknesses
As	far	as	we	know,	this	is	the	first	in-	depth	qualitative	study	to	ex-
amine	the	views	of	both	participants	with	ME/CFS	and	MS	on	what	
biomedical	 research	means	 to	 them,	 on	 future	 research	 priorities,	
and	approaches	to	sharing	and	publicizing	results.
A	 strength	 of	 using	 focus	 groups	 rather	 than	 individual	 inter-
views	was	the	extent	to	which	participants	were	able	to	interact	in	
their	 reflections,	 often	 eliciting	 richer	 and	more	 complex	 explora-
tion	of	 ideas	 as	 the	discussions	progressed29	However,	 our	 ability	
to	 include	 individuals	who	were	housebound	was	 limited	by	using	
this	approach	as	it	required	patients	to	be	well	enough	to	travel	to	a	
venue	for	the	group.	Focus	groups	may	also	limit	the	extent	to	which	
individuals	shared	opinions	differing	from	those	held	by	the	rest	of	
the	group.30
Purposive	sampling	ensured	that	 the	groups	 included	men	and	
women	of	different	ages,	 illness	durations	and	severities	of	 illness.	
However,	we	acknowledge	that	recruiting	participants	from	individ-
uals	already	participating	in	the	biomedical	research	of	the	UKMEB	
might	lead	to	higher	levels	of	awareness/comprehension	of	research	
than	the	wider	patient	population,	and	that	patients	who	were	new/
naive	to	research	might	have	expressed	different	views.31
In	 this	 study,	 all	 focus	 group	 facilitators	 were	 from	 CureME,	
whose	 remit	 is	 biomedical	 research.	 Analysis	 of	 transcripts	 sug-
gested	that	participants	appeared	to	concur	with	that	approach	for	
ME/CFS	 research.	 This	 is	 perhaps	 unsurprising,	 since	 participants	
were	 recruited	 from	 the	 larger	 sample	of	 those	 taking	part	 in	 the	
UKMEB.	 The	 remit	 of	 this	 study	 was	 to	 elicit	 participants’	 views	
Exemplifying quotes
Q42.	I	think	the	GP	needs	to	have	a	one	pager	of	what	it	is,	this	is	the	data	behind	it,	this	is	the	key	areas	of	
research.	(P16,	female,	ME,	group	3)
Q43.	“Have	you	read	the	latest	stuff?	They’ve	found	a	cure.”	No,	they	haven’t.	(P7,	male,	MS,	group	2)
Q44.	It	needs	to	be	very	to	the	point	and	positive,	but	like	you	say,	not	over	sensationalized.	(P26,	male,	MS,	
group	5)
Q45.I	mean	you’ll	be	making	decisions	about	how	much	to	let	out	and	when,	but	in	whatever	you	do	the	
communication	needs	to	be	talking	about	that	it	is	an	early	stage.	This	is	a	journey.	(P16,	female,	ME,	group	3)
Q46.	I	think	one	aspect	is	the	timing.	I	think	patients	are	quite	eager	to	see	Results,	as	soon	as	possible,	because	
everyone’s	looking	for	answers	and,	obviously,	there	are	key	things	going	on	right	now,	like	the	NICE	review.	
(P5,	male,	ME,	group	1)
Q47.	There’s	a	long	way	to	go	and	there’s	no	definite	answers	yet.	(P12,	female,	MS,	group	2)
Q48.	Whatever	research	comes	out,	the	research	team	is	always	very	quick	to	say,	they	really	want	to	big-	up	
their	own	efforts	and	they’ll	say,	“This	is	the	first	evidence	that	ME	is	biological.”	And	it’s	very	frustrating	to	
read	that	because	we	know	so	much	other	evidence	that	it’s	biological	and	it’s	not	fair	to	say	that’s	the	first.	
And	I	think	what	I’d	really	like	is	for	researchers	to	be	a	lot	more	collaborative,	to	talk	to	others,	to	build	on	what	
others	are	doing.	(P5,	male,	ME,	group	1)
Q49.	We	thought	it	was	really	impressive	that	you	come	out	and	engaged	with	us	as	sufferers	and	told	us	where	
you	are	and	promised	to	come	back	and	do	it	again,	very	impressive,	very	useful.	(P19,	male,	ME,	group	4)
Q50.	It	is	strange	to	think	or	to	say,	I	suppose,	that	in	discussing	this,	for	example,	with	my	boyfriend	or	my	
parents,	I	say,	“I	really	feel	honoured	to	take	part	in	this.”	This	to	me	seems	like	a	big	deal	that	each	of	those	
little	squares	on	that	grid,	one	of	those	was	me.	(P12,	female,	MS,	group	2)
Q51.	We’ve	got	our	interest	or	a	buy-	in	to	this	process.	(P24,	male,	MS,	group	5)
Q52.	We	haven’t	got	the	magical	cure	yet,	and	I	don’t	know	how	many	years	it’s	going	to	be,	but	we	do	have	such	
a	fantastic	resource	that	it	will	enable	much	more	research	to	be	done	in	ME/CFS,	and	in	MS,	by	having	these	
samples	all	collated	and	so	well	delineated.	(P8,	female,	MS,	group	2)
Q53.	It’s	whole	body	stuff.	So	I’m	really	glad	that	that	work’s	happening.	I	understand	it’s	really	hard	and	it	may	
take	quite	a	while	but	it’s	happening,	so	that’s	great.	(P16,	female,	ME,	group	3)
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specifically	 on	 biomedical	 research.	 Further	 qualitative	 research	
exploring	patients’	experiences	and	views	on	other	aspects	of	ME/
CFS	research,	particularly	interventions	for	ME/CFS,	would	help	to	
complete	a	fuller	picture	of	patient	views	regarding	future	research.
This	 study	 involved	 five	 focus	groups.	While	 there	 is	 little	 for-
mal	guidance	on	optimal	numbers	of	focus	groups,	a	study	by	Guest	
et	al	 found	 that	 80%	 of	 all	 themes	 were	 discoverable	 within	 two	
to	three	focus	groups,	and	90%	were	discoverable	within	 three	to	
six	 focus	groups.32	The	 three	ME/CFS	groups	and	two	MS	groups	
showed	marked	similarities	on	 the	 issues	 they	considered	of	most	
importance,	enhancing	credibility	that	the	findings	are	an	authentic	
portrait	of	 the	study	 topic.	Nevertheless,	we	do	not	consider	 that	
this	 study	 reached	 data	 saturation,	 since	 additional	 groups	 might	
have	elicited	fresh	views.
In	London,	the	ME/CFS	focus	groups	were	separated	into	male	
and	female	groups.	With	only	two	gender-	specific	focus	groups,	we	
are	unable	to	determine	whether	gender	affects	views	on	ME/CFS	
research.	However,	analysis	of	our	transcripts	suggests	that	if	such	
differences	exist,	they	are	relatively	subtle	and	would	need	a	much	
larger	study	to	make	comparisons.
The	study	included	more	ME/CFS	than	MS	participants	in	a	3:2	
ratio.	This	design	was	in	accordance	with	the	remit	of	CureME	and	
UKMEB,	which	were	established	for	accelerating	research	into	ME/
CFS.	MS	participants	were	made	aware	from	the	outset	that	the	re-
search	to	which	they	were	contributing	was	primarily	aimed	at	ME/
CFS,	though	with	the	possibility	that	results	might	also	help	people	
with	MS.	We	are	particularly	grateful	for	their	contributions	within	
this	context.
4.3 | How do these findings relate to existing 
literature?
Placing	patient	perspectives	at	the	centre	of	healthcare	research	has	
been	strongly	promoted	by	many	 international	policy	makers,28	as	
well	as	funders33	medical	journals34	and	research	institutions.
The	UK	organization	“INVOLVE”	was	established	by	the	National	
Institute	of	Health	Research	to	support	active	public	involvement	in	
medical	and	social	care	research	(invo.org.uk).	According	to	INVOLVE	
and	others,	well-	conducted	patient	and	public	involvement	(PPI)	can	
improve	 the	 relevance	 of	 research	 questions	 and	 patient	 recruit-
ment,	 leading	to	results	which	are	more	meaningful	for	patients,35 
and	increasing	chances	of	funding	and	dissemination.28
A	 growing	 body	 of	 international	 literature	 documents	 patient	
participation	 in	 identifying	 research	priorities	 in	many	diseases	 in-
cluding	HIV/AIDS,36	neurological	disabilities,	rheumatoid	arthritis37 
eczema,38kidney	disease,39	Parkinson’s	disease40,41	and	dementia.42
Various	 research	 approaches	 have	 been	 used	 to	 elicit	 patient	
views	on	research	priorities	including	focus	groups,43,44	PPI	consul-
tation	workshops45	and	expert	panels,46	as	well	as	structured	con-
sensus	seeking	methodologies	such	as	the	Delphi	technique.39,46,47 
In	this	study,	the	use	of	focus	groups	permitted	us	not	only	to	explore	
patient	views	on	research	priorities,	but	also	to	shed	light	on	some	
of	 the	 emotional	 and	 experiential	 reasons	 behind	 these	 priorities,	
helping	 to	 inform	our	understanding	of	 this	 complex	 topic.	At	 the	
same	time,	more	systematic	methodologies,	such	as	the	Delphi	tech-
nique,46	could	provide	more	structured	conclusions	on	research	pri-
orities	than	was	possible	in	this	study.
In	2017,	CureME	published	a	study	documenting	patient	partici-
pation	in	designing	the	UKMEB.2	The	current	study	follows	on	from	
that	work,	illuminating	patient	reactions	to	what	has	been	achieved,	
as	well	as	signposting	directions	for	the	future,	enabling,	participants	
to	become	active	partners	with	researchers,	rather	than	passive	“re-
search	subjects”	or	recipients	of	information.
4.4 | Implications for clinical practice
The	study	findings	highlight	 levels	of	distress	for	ME/CFS	patients	
experiencing	disabling	symptoms	of	a	disease	for	which	there	is	no	
proven	biomedical	 test,	 shared	by	MS	patients	with	delayed	diag-
nosis.	 Exploring	 the	 experiences	of	 two	patient	 groups	have	 shed	
light	on	some	unexpected	parallels,	which	bring	into	sharp	focus	the	
importance	of	how	patients	are	cared	for	when	diagnosis	is	unclear,	
and	 the	 deep	 distress	 caused	when	 patients	 feel	 not	 accepted	 or	
“held”	within	the	patient–doctor	relationship.
Cocksedge	 and	 colleagues	 have	 reflected	 on	 the	 doctor–pa-
tient	relationship	 in	complex	chronic	 illness,	highlighting	the	role	
of	GPs	in	“holding”	patients	at	times	of	uncertainty	and	fear,	even	
when	diagnosis	 is	 unclear	 and	uncertain	 and/or	 there	 is	 no	 cure	
for	the	 illness.48	Chew-	Graham	and	others	have	explored	the	di-
lemmas	 faced	 by	GPs	 in	making	 diagnosis	without	 confirmatory	
tests,49,50	 and	 the	 challenges	 to	 a	 GP’s	 role	 within	 a	 healthcare	
system	 in	which	 biomedical	 diagnosis	 is	 often	 a	 prerequisite	 for	
treatment	or	support.51
Several	of	the	MS	participants	with	a	delayed	diagnosis	described	
how	they	had	felt	judged	by	medical	professionals	and	others	as	in-
venting	or	exaggerating	symptoms,	an	attitude	which	transformed	
into	 supportive	 acceptance	 with	 a	 confirmed	 diagnosis	 of	 MS.	
Participants	 with	ME/CFS	 longed	 for	 a	 research	 breakthrough	 to	
achieve	a	similar	transformation.	These	mirrored	narratives	raise	the	
question	of	whether	more	progress	might	be	made	 in	 treating	 the	
patients’	accounts	as	trustworthy,	allowing	patients,	with	or	without	
current	diagnosis,	to	feel	validated	as	people	deserving	of	credence	
and	compassion	in	the	medical	relationship.
4.5 | Recommendations for future research
A	key	study	objective	was	to	find	out	what	patients	viewed	as	im-
portant	 in	 choosing	 directions	 for	 future	 research.	 The	 findings	
signpost	a	diversity	of	specific	topics,	including	investigating	sub-
groups	within	ME,	 immunological	 and	mitochondrial	 dysfunction	
the	 role	 of	 chemical	 and	 environmental	 triggers	 in	ME/CFS,	 and	
genetic,	 viral	 and	 immunological	 factors	 for	MS.	 These	 research	
topics	are	congruent	with	the	intentions	of	CureME	and	UKMEB,	
though	 the	 study	 adds	 specific	 suggestions	which	 the	 team	will	
endeavour	 to	 find	 ways	 of	 including	 within	 future	 research	
collaborations.
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Participants	called	for	researchers	to	be	 less	concerned	about	
claiming	 a	 “breakthrough”	 in	medical	 science	 for	 their	 own	work,	
and	to	put	greater	emphasis	on	contributing	to	a	collaborative	 in-
tegration	 of	 research	 knowledge	 which	 might	 one	 day	 lead	 to	 a	
biomedical	 test,	 effective	 treatments	 or	 cure.	 CureME	 hopes	 to	
fulfil	that	request,	not	only	in	future	dissemination,	but	in	all	inter-
actions	with	the	wider	research	community.	Ours	and	other	similar	
initiatives	 appear	 to	 indicate	 that	 the	 prevailing	 research	 culture	
is	changing	gradually	towards	the	collaborative	ethos	participants	
wish	to	see.
This	study	offers	a	compelling,	patient-	centred	argument	for	a	par-
adigm	shift	within	research	culture	towards	collaboration,	not	only	be-
tween	different	research	teams	but	between	patients	and	researchers.	
How	specifically	this	might	be	achieved	remains	a	subject	for	ongoing	
discussion	and	development	within	the	ME/CFS	and	MS	research	com-
munities,	but	the	participants	expressed	hope	that	their	contributions	
might	help	build	a	better	future	for	current	and	future	generations,	res-
onates	with	the	ethos	we	share	with	many	other	researchers.
5  | CONCLUSION
The	findings	of	this	study	provide	insight	into	the	emotional,	social	and	
practical	importance	of	research	to	MS	and	ME/CFS	patients	as	well	as	
suggesting	a	range	of	specific	research	topics	for	the	future.	Findings	
should	 inform	 the	 future	direction	not	only	of	 the	UKMEB,	but	also	
of	researchers	across	ME/CFS	and	MS	research,	adding	the	voices	of	
patients	to	a	call	for	developing	a	more	collaborative	research	culture.
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